Article thumbnail

Breast cancer prevention in women with a BRCA1 or BRCA2 mutation

By Kelly A Metcalfe and Steven A Narod
Topics: Clinical Practice
Publisher: Open Medicine Publications, Inc.
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2002). A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.
  2. (2005). A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev
  3. (2004). A high proportion of founder BRCA1 mutations in Polish breast cancer families.
  4. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
  5. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers:
  6. (1998). BRCA-associated breast cancer in young women.
  7. (2001). Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
  8. (2001). Breast cancer prevention with selective estrogen receptor modulators: a perspective.
  9. (1999). Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
  10. (2005). Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international casecontrol study.
  11. (2004). Breast MRI for women with hereditary cancer risk. JAMA
  12. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
  13. (2000). Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer.
  14. (2003). Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer
  15. (2001). Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.
  16. (2001). Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
  17. (2004). Efficacy of MRI and mammography for breastcancer screening in women with a familial or genetic predisposition.
  18. (2003). Evidence-based management options for women at increased breast/ovarian cancer risk. Ann Oncol
  19. (2000). First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat
  20. (1991). Genetic analysis of breast cancer in the cancer and steroid hormone study.
  21. (2001). Genetics Screening Committee. Ontario physicians' guide to referral of patients with family history of cancer to a familial cancer genetics clinic or genetics clinic. Ont Med Rev
  22. (2001). Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer.
  23. (2006). Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in
  24. (2002). Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer
  25. (2003). MRI of occult breast carcinoma in a high-risk population.
  26. (2002). Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
  27. (2000). Performance of screening mammography among women with and without a first-degree relative with breast cancer.
  28. (1998). Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet
  29. (1997). Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer.
  30. (2003). Probably benign lesions at breast magnetic resonance imaging: preliminary experience in high-risk women. Cancer
  31. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
  32. (1997). Recommendations for follow-up care of individuals with an inherited predisposition to cancer.
  33. (1998). Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann Oncol
  34. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
  35. (1998). Screening women aged less than 50 years with a family history of breast cancer.
  36. (2004). Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA
  37. (2001). Tamoxifen and breast cancer incidence among women with inherited mutations
  38. (2006). Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
  39. (2002). Tamoxifen for breast cancer prevention: safety warning.
  40. (1996). The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet
  41. (2001). The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography?.
  42. (1997). The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
  43. (2005). Time to reconsider subcutaneous mastectomy for breast-cancer prevention?. Lancet Oncol
  44. (2007). Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Med